相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Daratumumab induces mechanisms of immune activation through CD38+NK cell targeting
Domenico Viola et al.
LEUKEMIA (2021)
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
Meletios A. Dimopoulos et al.
LEUKEMIA (2021)
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
Maria-Victoria Mateos et al.
HAEMATOLOGICA (2020)
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
Priya Choudhry et al.
LEUKEMIA (2020)
PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Minsuk Kwon et al.
CLINICAL CANCER RESEARCH (2020)
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Nizar J. Bahlis et al.
LEUKEMIA (2020)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees et al.
BLOOD (2020)
Minimal PD-1 expression in mouse and human NK cells under diverse conditions
Sean J. Judge et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
Joseph Mikhael et al.
LEUKEMIA (2020)
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Saad Z Usmani et al.
Lancet Haematology (2020)
Distinct fibroblast subsets regulate lacteal integrity through YAP/TAZ-induced VEGF-C in intestinal villi
Seon Pyo Hong et al.
NATURE COMMUNICATIONS (2020)
Effects of Cryopreservation and Thawing on Single-Cell Transcriptomes of Human T Cells
Jeong Seok Lee et al.
IMMUNE NETWORK (2020)
Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing
Samantha L. Smith et al.
BLOOD ADVANCES (2020)
Memory-like natural killer cells for cancer immunotherapy
Margery Gang et al.
SEMINARS IN HEMATOLOGY (2020)
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Joseph Mikhael et al.
BLOOD (2019)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
Wenjuan Dong et al.
CANCER DISCOVERY (2019)
Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming
Aimee Merino et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Relapsed refractory multiple myeloma: a comprehensive overview
Abdul Hamid Bazarbachi et al.
LEUKEMIA (2019)
NK Cell Dysfunction and Checkpoint Immunotherapy
Jiacheng Bi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome
Chao Yang et al.
NATURE COMMUNICATIONS (2019)
Bone marrow transplantation generates T cell-dependent control of myeloma in mice
Slavica Vuckovic et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection
Anita Schuch et al.
JOURNAL OF HEPATOLOGY (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
Phenotypic and Functional Analysis of Human NK Cell Subpopulations According to the Expression of FcεRIγ and NKG2C
Kyung Hwan Kim et al.
FRONTIERS IN IMMUNOLOGY (2019)
Adaptive NK cell reconstitution is associated with better clinical outcomes
Frank Cichocki et al.
JCI INSIGHT (2019)
Daratumumab in untreated newly diagnosed multiple myeloma
Nadine Abdallah et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model
Camille Guillerey et al.
JCI INSIGHT (2019)
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
C. S. Chim et al.
LEUKEMIA (2018)
TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma
Camille Guillerey et al.
BLOOD (2018)
Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation
Sarah Cooley et al.
BLOOD (2018)
Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells
Yufeng Wang et al.
CLINICAL CANCER RESEARCH (2018)
The multiple myelomas - current concepts in cytogenetic classification and therapy
Shaji K. Kumar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Daratumumab for the Treatment of Multiple Myeloma
Torben Plesner et al.
FRONTIERS IN IMMUNOLOGY (2018)
Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade
Simone A. Minnie et al.
BLOOD (2018)
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Niels W. C. J. van de Donk et al.
FRONTIERS IN IMMUNOLOGY (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice
Adeline Crinier et al.
IMMUNITY (2018)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
Kerry S. Campbell et al.
FRONTIERS IN IMMUNOLOGY (2018)
Natural killer cells and other innate lymphoid cells in cancer
Laura Chiossone et al.
NATURE REVIEWS IMMUNOLOGY (2018)
The Broad Spectrum of Human Natural Killer Cell Diversity
Aharon G. Freud et al.
IMMUNITY (2017)
Redefining Memory: Building the Case for Adaptive NK Cells
Silke Paust et al.
JOURNAL OF VIROLOGY (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
S. Lonial et al.
LEUKEMIA (2016)
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2016)
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof et al.
BLOOD (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Natural killer cell memory in infection, inflammation and cancer
Adelheid Cerwenka et al.
NATURE REVIEWS IMMUNOLOGY (2016)
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2015)
Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function
Heinrich Schlums et al.
IMMUNITY (2015)
Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected Individuals
Jaewon Lee et al.
IMMUNITY (2015)
Antibody-Mediated Response of NKG2Cbright NK Cells against Human Cytomegalovirus
Marcel Costa-Garcia et al.
JOURNAL OF IMMUNOLOGY (2015)
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
Inger S. Nijhof et al.
CLINICAL CANCER RESEARCH (2015)
Signatures of human NK cell development and terminal differentiation
Merlin Luetke-Eversloh et al.
FRONTIERS IN IMMUNOLOGY (2013)
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
Don M. Benson et al.
BLOOD (2011)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Frits van Rhee et al.
MOLECULAR CANCER THERAPEUTICS (2009)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
分享论文
